O antagonista do receptor de neuroquinina-1 aprepitante diminui a eficácia da quimioterapia baseada em ciclofosfamida?

Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the preven- tion of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005;41(9):1278-85.

Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after mode- rately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822-30.

van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat. 2008;11(3):77-98.

de Jonge ME, Huitema AD, Holtkamp MJ, van Dam SM, Beijnen JH, Rodenhuis S. Aprepi- tant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol. 2005;56(4):370-8.

Yeo W, Mo FK, Suen JJ, et al. A randomized study of aprepitant, ondansetron and dexametha- sone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients recei- ving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009;113(3):529-35.